CN114302881B - 适用于治疗和预防肌肉萎缩和其他状况的化合物 - Google Patents

适用于治疗和预防肌肉萎缩和其他状况的化合物 Download PDF

Info

Publication number
CN114302881B
CN114302881B CN202080057706.5A CN202080057706A CN114302881B CN 114302881 B CN114302881 B CN 114302881B CN 202080057706 A CN202080057706 A CN 202080057706A CN 114302881 B CN114302881 B CN 114302881B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
methyl
muscle
myomed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080057706.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN114302881A (zh
Inventor
沃尔克·亚当斯
西格弗里德·拉贝特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN114302881A publication Critical patent/CN114302881A/zh
Application granted granted Critical
Publication of CN114302881B publication Critical patent/CN114302881B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080057706.5A 2019-08-16 2020-08-14 适用于治疗和预防肌肉萎缩和其他状况的化合物 Active CN114302881B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19192107.1 2019-08-16
EP19192107 2019-08-16
PCT/EP2020/072911 WO2021032643A1 (en) 2019-08-16 2020-08-14 Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions

Publications (2)

Publication Number Publication Date
CN114302881A CN114302881A (zh) 2022-04-08
CN114302881B true CN114302881B (zh) 2025-03-25

Family

ID=67659191

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080057706.5A Active CN114302881B (zh) 2019-08-16 2020-08-14 适用于治疗和预防肌肉萎缩和其他状况的化合物

Country Status (13)

Country Link
US (1) US12331042B2 (https=)
EP (1) EP4013497B1 (https=)
JP (1) JP2022544803A (https=)
KR (1) KR20220047807A (https=)
CN (1) CN114302881B (https=)
AU (1) AU2020334194A1 (https=)
BR (1) BR112022002769A2 (https=)
CA (1) CA3144700A1 (https=)
CL (1) CL2022000320A1 (https=)
IL (1) IL290540A (https=)
MX (1) MX2022002022A (https=)
WO (1) WO2021032643A1 (https=)
ZA (1) ZA202202863B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102823820B1 (ko) * 2022-09-01 2025-06-23 단국대학교 천안캠퍼스 산학협력단 퓨로크로멘온계 화합물을 유효성분으로 포함하는 근감소증 예방 또는 치료용 약학 조성물
AU2023348158A1 (en) * 2022-09-30 2025-02-27 Société des Produits Nestlé S.A. Composition and method for treating muscle decline associated with renal disease or dysfunction

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112274183A (zh) * 2020-11-02 2021-01-29 李云莹 一种神经内科用脑部超声波治疗装置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2624524C (en) * 2005-09-29 2014-07-08 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
EP2072528A1 (en) 2007-12-19 2009-06-24 Labeit, Mr. Siegfried A host cell deficient for MuRF1 and MuRF2
WO2012154213A1 (en) * 2011-04-07 2012-11-15 Cornell University Cofluorons and methods of making and using them
AU2012268036B2 (en) * 2011-06-06 2017-04-06 THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF STATE OF THE DEPARTMENT OF VETERANS AFFAIRS Methods of inhibiting muscle atrophy
AU2014290368B2 (en) 2013-07-18 2019-07-11 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
WO2015050984A1 (en) * 2013-10-01 2015-04-09 New York University Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112274183A (zh) * 2020-11-02 2021-01-29 李云莹 一种神经内科用脑部超声波治疗装置

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Small-Molecule Inhibition of MuRF1 Prevents Early Disuse-Induced Diaphragmatic Dysfunction and Atrophy;Fernando Ribeiro, 等;Int J Mol Sci .;20230211;第24卷(第04期);3637 *
秦娇,等.无过渡金属催化的α-溴代茚酮自由基裂解反应合成(2-氰基苯基)乙酸-2,2,6,6-四甲基哌啶酯.有机化学. .2023,第43卷(第06期),2171-2177. *

Also Published As

Publication number Publication date
AU2020334194A1 (en) 2022-02-24
US12331042B2 (en) 2025-06-17
WO2021032643A1 (en) 2021-02-25
JP2022544803A (ja) 2022-10-21
EP4013497B1 (en) 2023-10-04
EP4013497C0 (en) 2023-10-04
EP4013497A1 (en) 2022-06-22
US20220324852A1 (en) 2022-10-13
CN114302881A (zh) 2022-04-08
KR20220047807A (ko) 2022-04-19
CL2022000320A1 (es) 2023-02-03
ZA202202863B (en) 2023-10-25
CA3144700A1 (en) 2021-02-25
MX2022002022A (es) 2022-05-11
BR112022002769A2 (pt) 2022-05-10
IL290540A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
US12319684B2 (en) Agonists of the apelin receptor and methods of use thereof
ES2972487T3 (es) Formas sólidas de un inhibidor de tienopirimidindiona acc y métodos para la producción del mismo
JP5423675B2 (ja) アゾール化合物
BR112016009488B1 (pt) piperidil-etil-pirimidina substituída, seus usos, e composição farmacêutica
WO2012075678A1 (zh) 取代噻唑基吡唑并吡啶类化合物及其医药用途
BR112021000938A2 (pt) composto sal farmaceuticamente aceitável, tautômero, isômero ou estereoisômero do mesmo, composição farmacêutica e processo para a síntese do dito composto
CN114302881B (zh) 适用于治疗和预防肌肉萎缩和其他状况的化合物
CZ20032287A3 (cs) Způsoby léčení zánětlivých a imunitních nemocí za použití inhibitorů IkB kinázy (IKK)
US12006321B2 (en) Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists
RU2542980C2 (ru) Замещенные производные 3-бензофуранил-индол-2-он-3-ацетамидопиперазинов, их получение и их применение в терапии
EA034427B1 (ru) Производные индола
TWI839385B (zh) 肥胖症的治療
WO2026033305A1 (en) Fused bicyclic heterocyclic derivatives as hdac inhibitors
CN108290868A (zh) 1,4-二-(4-甲硫基苯基)-3-邻苯二甲酰氮杂环丁烷-2-酮及其衍生物
HK40125827A (zh) 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法
CN116601166A (zh) 环Apelin受体激动剂
HK40055242A (zh) 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant